ACA marketplaces remain unstable—but insurers see profit potential

Prices continue to climb on the Affordable Care Act exchanges, with some estimates calling for 30 percent increases to typical silver-level plans in 2019. But despite the additional challenges faced by individuals on the marketplaces, insurers see clear skies ahead.

An article by the Hill details how insurance companies are reentering the ACA marketplaces despite the Trump administration’s hostility toward the ACA.

“We have finally reached the point where insurers are making money in the [ACA] marketplaces,” said Larry Levitt, a senior vice president at the Kaiser Family Foundation, in an interview with the Hill. “The market is stable economically, but it’s stabilized where premiums are very expensive.”

At the link below read more about how experts are feeling more certain in the federal interpretation of the ACA, while the regulatory situation continues to be messy.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.